34.16
price up icon0.29%   0.06
 
loading

Galapagos Nv Adr Aktie (GLPG) Neueste Nachrichten

pulisher
Oct 09, 2025

How Have Insiders Been Trading Winmark Corporation (WINA) Stock? - fostersleader.com

Oct 09, 2025
pulisher
Oct 09, 2025

Why You Need Galapagos NV ADR (GLPG) On Your Watchlist - fostersleader.com

Oct 09, 2025
pulisher
Oct 09, 2025

Stock on Demand This Week: Hour Loop Inc (HOUR) - fostersleader.com

Oct 09, 2025
pulisher
Oct 09, 2025

Is Buying Stock In Radiopharm Theranostics Ltd ADR (RADX) A Good Move Today? - fostersleader.com

Oct 09, 2025
pulisher
Oct 09, 2025

SolarMax Technology Inc (SMXT): What Does Valuation Ratios Tell Us? - fostersleader.com

Oct 09, 2025
pulisher
Oct 02, 2025

Galapagos Updates on Cell Therapy Business Strategic Review - The Globe and Mail

Oct 02, 2025
pulisher
Aug 06, 2025

Galapagos (0JXZ) was downgraded to a Sell Rating at Deutsche Bank - The Globe and Mail

Aug 06, 2025
pulisher
Jul 25, 2025

Galapagos NV Reports Strong H1 2025 Results Amid Strategic Transformation - The Globe and Mail

Jul 25, 2025
pulisher
Jul 24, 2025

Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com

Jul 24, 2025
pulisher
Jul 24, 2025

Raymond James reiterates Market Perform rating on Galapagos stock By Investing.com - Investing.com South Africa

Jul 24, 2025
pulisher
Jul 23, 2025

Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com

Jul 23, 2025
pulisher
Jun 05, 2025

Planisware expands into Belgium to support the sustained growth of its business in the Benelux region - GlobeNewswire Inc.

Jun 05, 2025
pulisher
May 14, 2025

Galapagos stock holds as CEO change, spinoff plans halted By Investing.com - Investing.com India

May 14, 2025
pulisher
May 13, 2025

Galapagos stock holds as CEO change, spinoff plans halted - Investing.com

May 13, 2025
pulisher
May 08, 2025

Ratios in Focus: Analyzing Galapagos NV ADR (GLPG)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

May 08, 2025
pulisher
Apr 24, 2025

Galapagos stock holds Market Perform rating at Raymond James - Investing.com

Apr 24, 2025
pulisher
Jan 21, 2025

Galapagos To Spin Off Innovative Medicines Business - Forbes

Jan 21, 2025
pulisher
Jan 09, 2025

Belgium stocks higher at close of trade; BEL 20 up 0.06% - Investing.com

Jan 09, 2025
pulisher
Nov 20, 2024

Galapagos stock downgraded to Reduce on strategic concerns - Investing.com

Nov 20, 2024
pulisher
Aug 26, 2024

Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats - Investor's Business Daily

Aug 26, 2024
pulisher
Aug 02, 2024

Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com

Aug 02, 2024
pulisher
Jun 17, 2024

Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com

Jun 17, 2024
pulisher
May 30, 2024

Adaptimmune and Galapagos partner on cancer therapy - Investing.com

May 30, 2024
pulisher
May 06, 2024

Earnings call: Galapagos outlines strategic focus in Q1 2024 results - Investing.com

May 06, 2024
pulisher
Dec 02, 2022

Billionaire hedge fund manager David Einhorn’s portfolio revealed - Daily Investor

Dec 02, 2022
pulisher
Jun 21, 2022

+ND Capital's European Investment Strategy Delivers Again as Sale of CellPoint to Galapagos Paves the Way for Disruptive Point-of-Care Cell Therapy Model for Cancer Patients - Barchart.com

Jun 21, 2022
pulisher
Mar 25, 2022

GLPG Stock Price and Chart — EURONEXT:GLPG - TradingView

Mar 25, 2022
pulisher
Jul 31, 2020

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates - Benzinga

Jul 31, 2020
pulisher
Feb 11, 2020

The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology - Yahoo Finance

Feb 11, 2020
pulisher
Jul 27, 2018

AIM tech shares that broke America - Interactive Investor

Jul 27, 2018
pulisher
Jul 19, 2018

Novartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitis - Novartis

Jul 19, 2018
pulisher
Dec 30, 2015

The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes

Dec 30, 2015
$84.60
price up icon 0.95%
$22.91
price up icon 7.03%
$32.47
price up icon 2.06%
$102.55
price up icon 0.63%
$166.10
price up icon 2.22%
biotechnology ONC
$331.09
price up icon 3.45%
Kapitalisierung:     |  Volumen (24h):